Home>Topics>Companies>Allergan

Allergan AGN

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Global Diabetic Retinopathy Market 2015 - Global Market Size, Trends, Development, and Forecasts to 2019

      Commentary

      Tue, 21 Apr 2015

      International Inc. Other Prominent Vendors - Abbott Laboratories Ltd. - Alcon Laboratories Inc. - Alimera Sciences Inc. - Allergan Inc . - Ampio Pharmaceuticals Inc. - Antisense Therapeutics Ltd. - Bausch & Lomb Inc. - BCN Peptides SA - Boehringer

    2. Mylan Makes Offer for Perrigo in Attempt to Diversify Generic Operations

      Commentary

      Wed, 8 Apr 2015

      Procter & Gamble combined with Actavis’ and Valeant’s high financial leverage after their recent deals for Salix and Allergan , respectively, could hinder additional bids. We’re raising our stand-alone fair value estimate for Perrigo to $150

    3. Health Care: 3 Picks in a More Expensive Sector

      Headlines

      Wed, 1 Apr 2015

      through creating scale, cutting costs, and focusing on key strategic areas. We see this trend with the pending acquisition of Allergan by Actavis. This trend is also evident with Valeant 's VRX bid for Salix (which may subsequently get outbid by Endo ENDP

    4. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

      Headlines

      Mon, 23 Mar 2015

      wide-moat operations following the Allergan acquisition. From Weak Generic to Major ..... Irish domicile. With the close of the Allergan acquisition, Actavis will have pro forma ..... flow in excess of $8 billion. Legacy Allergan , Forest, and Warner sales will represent

    5. A Wide-Moat Opportunity in Health Care

      Video Reports

      Wed, 11 Mar 2015

      with pro forma sales after the Allergan ( AGN ) deal on par with big players ..... a lot of that is inherited from Allergan , but we think there is a lot of ..... cost synergies from the recent Allergan deal. We currently have a $330

      Allergan AGN found at 0:18

      to a very large branded-pharmaceutical firm with pro forma sales after the Allergan ( AGN ) deal on par with big players like Eli Lilly (LLY) and GlaxoSmithKline (GSK). We like the business and we give it a
    6. Complexities of Eye Care Drive Strong Moats

      Headlines

      Fri, 6 Mar 2015

      ophthalmology drugmakers, especially Allergan AGN and Novartis, have enjoyed success ..... rolling out new dosage strengths ( Allergan 's Lumigan 0.03% to 0.01 ..... preservative-free products ( Allergan 's Alphagan to Alphagan P

    7. Ultimate Stock-Pickers' Top 10 Buys and Sells

      Headlines

      Tue, 3 Mar 2015

      WellsFargo WFC 3 Medium Narrow 54.79 1.05 282,581 5 Allergan AGN 3 Medium Wide 232.74 1.03 70,358 3 Occidental ..... acquisitions announced during the period (with wide-moat Allergan AGN fitting the bill this time around). With regards to

    8. Compelling Financial Benefit in Valeant's Latest Buy

      Headlines

      Fri, 27 Feb 2015

      six-year-plus record of success to be encouraging. He has demonstrated a willingness and ability to walk away from a target ( Allergan , Cephalon, and so on) and avoids bidding wars whenever possible. He lacks a scientific background or experience in research

    9. Actavis Reports Strong Fourth Quarter Heading Into Allergan Acquisition

      Commentary

      Wed, 18 Feb 2015

      in 2015 as the planned acquisition of Allergan remains on track for early this year despite ..... billion in revenue for 2015 before the Allergan deal. We continue to think Actavis earns ..... economic moat thanks to the inheritance of Allergan ’s defensible branded products and pipeline

    10. Undervalued Valeant's Unique Strategy Is Underappreciated

      Video Reports

      Wed, 18 Feb 2015

      stewardship rating. They have shown they are willing to walk away when deal prices get too high, which we saw recently with Allergan ( AGN ), as well as a number of other times over the last six years. They have also shown a willingness to buy back their

      Allergan AGN found at 0:56

      away when deal prices get too high, which we saw recently with Allergan ( AGN ), as well as a number of other times over the last six years. They have also shown a willingness to buy back
    « Prev12345Next »
    Content Partners